Publicaciones en las que colabora con Alejandro Martín García Sancho (21)

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  2. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211

2022

  1. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  2. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

    Cancers, Vol. 14, Núm. 11

  3. TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399

2021

  1. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  2. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 542-551

2019

  1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  2. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  3. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

2017

  1. Plitidepsin: Design, development, and potential place in therapy

    Drug Design, Development and Therapy, Vol. 11, pp. 253-264

  2. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

    Hematological Oncology, Vol. 35, Núm. 4, pp. 520-527

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2015

  1. Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León

    Medicina Clinica, Vol. 144, Núm. 11, pp. 491-500

2012

  1. Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 4, Núm. 1

2009

  1. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: Influence of prior autologous stem-cell transplantation on outcome

    Haematologica

2006

  1. Treatment options in relapsed or refractory Hodgkin disease patients: The mini-BEAM regimen does exist too [1]

    British Journal of Haematology

2005

  1. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma

    Haematologica, Vol. 90, Núm. 1, pp. 78-85

2004

  1. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: A single-centre sequential-cohort study

    Bone Marrow Transplantation, Vol. 34, Núm. 8, pp. 675-682

2001

  1. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease

    British Journal of Haematology, Vol. 113, Núm. 1, pp. 161-171